Cancer vaccine MUC-1 - Immutep Limited
Alternative Names: CVac; M-FP cancer vaccine; Mannan-MUC1 fusion protein; MUC1 dendritic cell vaccineLatest Information Update: 02 Oct 2021
At a glance
- Originator Prima Biomed
- Developer Immutep Limited; Prima BioMed
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Ovarian cancer
- Discontinued Pancreatic cancer